key: cord-1004679-03934azx authors: Tleyjeh, Imad M.; Kashour, Zakariya; Riaz, Muhammad; Hassett, Leslie; Veiga, Viviane C.; Kashour, Tarek title: Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic Review and meta-analysis: first update date: 2021-04-27 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2021.04.019 sha: 8a72e8961c47dc7c54884eb450caa2ac110b0cff doc_id: 1004679 cord_uid: 03934azx BACKGROUND: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). OBJECTIVES: To update data a living systematic review of the literature concerning the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients. DATA SOURCES: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Web of Science, Scopus up, preprint servers and Google from October 8, 2020 till February 24, 2021. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) and observational studies at low or moderate risk of bias. PARTICIPANTS: Hospitalized COVID-19 patients. INTERVENTIONS: Tocilizumab versus placebo or standard of care. METHODS: We pooled crude risk ratios (RRs) of RCTs with random effects model and evaluated inconsistency between studies with I(2). We assessed the certainty of evidence using the GRADE approach. RESULTS: Of 1600 citations, 8 RCTs and 28 cohorts were eligible. The 8 RCTs, at low risk of bias, with 6311 patients examined the effect of tocilizumab on short-term mortality; pooled RR was 0.91 (95%CI 0.78, 1.07, I(2) = 25%). Only the REMAP-CAP and RECOVERY trials with the majority of their patients on concomitant corticosteroids, showed lower 30-day mortality with tocilizumab use, RR 0.74 (95%CI 0.59, 0.93) and 0.89 (95%CI 0.81, 0.97), respectively. Seven RCTs, with 5391 patients examined the effect of tocilizumab on risk of mechanical ventilation; pooled RR was 0.84 (95% CI 0.76, 0.93), I(2) = 0%, with a corresponding number needed to treat of 20 (95%CI 14.3–33.3). Eight RCTs, with 5,340 patients, examined the effect of tocilizumab on a composite of poor outcome; pooled RR was 0.82 (95% CI 0.76, 0.90, I(2) = 3%). Data from the RCTs showed a lower risk of infections and no higher risk of serious adverse events with tocilizumab; pooled RR 0.67 (95%CI 0.45, 0.99, eight RCTs) and 0.85 (95%CI 0.63, 1.16, seven RCTs), respectively. Among 28 cohorts with 15484 patients, the pooled adjusted RR for mortality was 0.53 (95%CI 0.43, 0.67, I(2) = 76%). CONCLUSIONS: Cumulative high certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized patients with severe COVID-19. Moderate certainty evidence shows that tocilizumab reduces the risk of poor outcome and the risk of secondary infections in hospitalized COVID-19 patients. This review will continuously evaluate the role of tocilizumab in COVID-19 treatment. Interventions: Tocilizumab versus placebo or standard of care. We pooled crude risk ratios (RRs) of RCTs with random effects model and evaluated inconsistency between studies with I 2 . We assessed the certainty of evidence using the GRADE approach. Of 1600 citations, 8 Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID- 19) . As of October 2020, cumulative moderate-certainty evidence from randomized controlled trials (RCTs) showed that the IL-6 receptor antagonist (tocilizumab) reduces the risk of mechanical ventilation in hospitalized COVID-19 patients, without affecting short-term mortality 1 . This report is the first update of our living systematic review assessing the efficacy and safety of tocilizumab in COVID-19 patients 1 . Using the same methodology and search databases detailed in our previous review 1 , we searched for new studies published through 24 February 2021 and updated our analysis using the same quality assessment tools and analytical methods. Since several randomized controlled trials (RCTs) have been published after our initial review, and as per peer reviewers' and editor's recommendations, this update included observational studies up to January 2021 and future updates will only include data from RCTs. We also contacted all first authors of eligible RCTs for additional data for subgroup analyses. We evaluated an additional 1600 abstracts from peer reviewed publications. We also searched for unpublished manuscripts using the medRxiv services and Researchsquare.com, Google, and the references of eligible studies and review articles. Only one author responded to our queries for additional data for subgroup analyses. We identified eight multicenter RCTs 2-9 ; of which one was stopped early for possible futility 9 In addition, we identified 10 additional cohort studies since our first review [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . A total of 28 cohort studies, at moderate risk of bias, reported on adjusted effect estimates of mortality. Supplementary Material Tables S1 illustrates the general characteristics of the included cohort studies. All studies reported on patients hospitalized with COVID-19 with varying degrees of disease severity. suggest that tocilizumab is associated with reduced risk of secondary infections, and a composite of poor outcome. Certainty of evidence was downgraded due to a wide confidence interval in the RR of infection, and due to possible performance bias for outcomes such as ICU admission in the composite outcome. We observed with moderate certainty that tocilizumab has no significant effect on mortality. The pooled RR of 0.91 (95%CI 0.72, 1.07) was imprecise, with a wide 95%CI, suggesting that more studies may be needed for a definitive answer. For the cohort studies, the overall quality of evidence (classified as low in observational studies) remained low given the moderate risk of study bias, low risk of publication bias, direct evidence, low inconsistency, and precise estimate. Although I 2 was high for the pooled mortality risk estimate, it was driven by the magnitude of the association rather than its direction. In this updated systematic review and meta-analysis of 8 RCTs, as of February 2021, we observed with high certainty that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. We also observed, with moderate certainty, that tocilizumab reduces the risk of poor outcome and the risk of secondary infections in hospitalized COVID-19 patients. We discuss in our prior review 1 the possible molecular mechanisms for this observed effect. We did not observe a significant effect of tocilizumab on the risk of mortality or adverse events. Only the 2 largest RCTs, the RECOVERY 6 and REMAP-CAP 8 , with more than 80% of their patients treated concomitantly with corticosteroids, showed an improved survival in patients receiving tocilizumab. We could not examine the interaction between corticosteroids use, mechanical ventilation, timing of tocilizumab, inflammatory markers, and the effect of tocilizumab on different outcomes. We contacted all authors of the 8 RCTs asking them for data for different subgroups; only one author provided us with the needed data. Despite the 8 published trials in the past year, it is still difficult to specify which population will benefit from tocilizumab in COVID-19. Ambiguity is compounded when taking into consideration the differences in trial designs such as inclusion criteria of patients with different disease severity and the temporal trends in standard of care such as the use of steroids (Table) . There are many variables that may dictate who will benefit from tocilizumab treatment such as patients' characteristics, disease severity, timing of treatment, and duration of illness (Table) . Data from the RECOVERY trial showed that the survival benefit was restricted to patients who Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis Tocilizumab in hospitalized patients with COVID-19 pneumonia Tocilizumab in patients hospitalized with covid-19 pneumonia. The New England journal of medicine Efficacy of tocilizumab in patients hospitalized with covid-19 Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, openlabel Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial Interleukin-6 receptor antagonists in critically ill patients with covid-19 Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort) A propensity-matched cohort study of tocilizumab in patients with coronavirus disease 2019 Matched cohort study on the efficacy of tocilizumab in patients with COVID-19. One Health Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: A multicentre cohort study (SAM-COVID-19) Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A spanish, multicenter, cohort study. Infectious diseases and therapy Repurposed tocilizumab in patients with severe COVID-19 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 COVID-19) Treatment Guidelines. National Institutes of Health Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) TOCIBRAS NCT04403685 Open label: 65 TCZ vs. 64 Controls Nine hospitals in Brazil Severe to critical High inflammatory marker: Yes Progressive disease: No 16% 69% 73% label: 2022 TCZ vs -13) based on NIH classification for the majority of patients, b) From symptoms onset The authors declare no conflicts of interest. No funding was received for this work.J o u r n a l P r e -p r o o f